2nd ATST Meeting
Allogeneic Transplantation in Solid Tumors
Grand Hotel Bristol, October 7-8, 2005Stresa - Italy
PRELIMINARY PROGRAMMEUnder the auspices of
www.sanraffaele.org Section “Care” - Section “Conferences”
Meeting VenueGrand Hotel BristolCorso Umberto I, 73Stresa - Lago Maggiore - Italy
Scientific SecretariatDr. Marco Bregni, Dr. Massimo Bernardi, Dr. Jacopo Peccatori UTMO - Bone Marrow Transplantation UnitSan Raffaele Scientific InstituteVia Olgettina, 60 - 20132 Milano - Italye-mail [email protected]
Organising SecretariatSan Raffaele Congress CentreVia Olgettina, 58 - 20132 Milano - ItalyPhone +39 02 2643 3700 Fax +39 02 2643 3754e-mail [email protected]
Official LanguageMeeting official language will be English. Simultaneous translation will notbe provided.
C.M.E. - Continuous Medical EducationThe Italian Ministry of Health will be requested to evaluate the meeting forC.M.E. The credits will be reserved only to Italian specialists in hematology,oncology and immunology.
RegistrationsTo register for the meeting, please send the enclosed registration form, dulyfilled in, to the Organising Secretariat together with the proof of payment.Registration fee covers attendance to the scientific sessions, attendancecertificate, lunch and coffee-break during the meeting.
Cancellations and RefundsNotification of cancellation must be made in writing to the OrganisingSecretariat. Refunds will be carried out after the meeting, by bank transfer,as follows:• Prior to September 7, 2005 - full refund (less Euros 20,00 for Secretariat
expenses)• Between September 7 and September 30, 2005 - 50% of fees paid• After September 30, 2005 - NO REFUND
Registration Desk/SecretariatAll documents will be handed over to registered partecipants on FridayOctober 7, 2005 - starting from 1.30 p.m. - at Grand Hotel Bristol in Stresa.
General informationHotel accommodationGrand Hotel BristolThe hotel has reserved an allotment of rooms for the meeting, according tothe following rates:
• double room for single use Euros 145,00 b/b (VAT included) per room, per night
• double room Euros 200,00 b/b (VAT included) per room, per night
All participants interested in making a reservation, should contact directly
Grand Hotel Bristol - Congress DepartmentPhone +39 0323 913983 - Fax +39 0323 913837e-mail [email protected]
referring to the 2nd ATST Meeting. A credit card number will be requested to guarantee the booking.Please be informed that the number of rooms reserved is limited; requestsof accommodation will be granted on a “first come, first served” basis.
If you would like to book another hotel in Stresa, please visit for informationthe web site www.stresa.org/eng
How to reach Stresa• Train
Stresa lies on the International Railway Line Milano-Domodossola-Brig(continuing to Geneva or Basel), which is served by frequent IC and ECtrains. To check timetable, please visit the web site of The EuropeanRailway Server - www.railfaneurope.net
• PlaneThe International Airport of Milano Malpensa is connected to Stresa by a comfortable bus service. To check timetable, please visit the web site www.safduemila.com - Section “Orari” - Section “Servizio ALIBUSVebania/Malpensa 2000”.
• CarParticipants coming by car from Italy can reach Stresa either from Milano(highway A8 - Autostrada dei Laghi) or from Genova and Torino (highwayA26): direction Gravellona Toce, exit Carpugnino or Gravellona. If ente-ring Italy through Switzerland, either via Brig-Simplon or Gotthard-Locarno,just follow direction Milano. Associazione Italiana
di Oncologia Medica
Scientific programme
October 7, 2005
Chairmen: Richard W. Childs, Marco Bregni, Naoto T. Ueno
Scientific Committee: Dietger Niederwieser, Taner Demirer, Didier Blaise, Paolo Corradini, Salvatore Siena
3.00 pm Welcome and Introduction R.W. Childs
3.10 pm SESSION 1What's new in immunotherapy for cancer?Chairmen: S. Slavin, P. Corradini
3.15 pm Lymphodepleting therapy and TIL N. Restifo
3.40 pm Regulatory T-cells M.G. Roncarolo
4.05 pm NK cells A. Velardi
4.30 pm SESSION 2Update on conventional therapy and NST for RCC, Breast, and Ovarian CancerChairmen: S. Siena, D. Blaise
• Renal cancerState-of-the art: B. EscudierAllografting: R.W. Childs, A.S. Artz
• Breast cancerState-of-the art: M. ColleoniAllografting: M.R. Bishop, N.T. Ueno
• Ovarian cancerState-of-the art: J.A. LedermannAllografting: J. Bay, M. Bregni
9.00 am SESSION 3Graft-vs Solid Tumor-From Mouse to ManChairmen: D. Montagna, D. Niederwieser• Animal Models S. Slavin• Tumor-antigen specific T-cell receptors M.I. Nishimura • Identification of RCC-reactive Y. Takahashi
T-cells in humans after NST E.D. Wieder• Immunogenic peptides on breast cancer
cells as targets for the GvT effect D. Niederwieser
11.00 am Coffee break
11.15 am SESSION 4Graft-vs-Solid Tumor: Anecdotal reportsChairmen: G. Rosti, T. Demirer• Soft tissue sarcoma P. Pedrazzoli• Pancreatic cancer Y. Kanda• Prostate cancer I M. Bregni• Prostate cancer II L.M. Barkholt• Colon cancer M. Aglietta
12.45 pm Lunch
1.45 pm SESSION 5Optimizing Transplant OutcomeChairmen: P. Pedrazzoli, O. Ringdén• Reanalysis of a large series of NST in breast
and renal cancer D. Blaise• Role of Pretransplant Tumor Debulking R.W. Childs • Auto/allo approaches A.M. Carella• Selective immunodepletion J.A. Barrett• Targeting donor T-cells against cancer S. Slavin• Adoptive NK cell approaches F. Re
3.45 pm SESSION 6Future directionsChairmen: J.A. Barrett, B.M. Sandmaier• MUD protocols O. Ringdén
N.T. Ueno• Standardizing forms for reporting D. Niederwieser• Cooperative clinical trials Round Table
4.45 pm Meeting adjourns
October 8, 2005 Massimo AgliettaIstituto per la Ricerca e la Cura delCancro - Candiolo (TO), Italy
Andrew S. Artz The University of Chicago - Chicago, USA
Lisbeth M. Barkholt Huddinge University Hospital, Huddinge, Sweden
John A. BarrettNational Institutes of Health - Bethesda, USA
Jacques-Olivier Bay Centre Jean Perrin - CHU - Clermont-Ferrand, France
Michael R. Bishop National Institutes of Health - Bethesda, USA
Didier Blaise Institut Paoli-Calmettes - Mareseille, France
Marco BregniIstituto Scientifico Universitario San Raffaele - Milano, Italy
Angelo Michele CarellaOspedale San Martino - Genova, Italy
Richard W. Childs National Institutes of Health - Bethesda, USA
Marco ColleoniIstituto Europeo di Oncologia - Milano, Italy
Paolo Corradini Istituto Nazionale per lo Studio e la Cura dei Tumori - Milano, Italy
Taner Demirer Ankara University Medical School - Ankara, Turkey
Bernard EscudierInstitut Gustave Roussy - Villejuif, France
Yoshinobu KandaThe University of Tokyo - Tokyo,Japan
John A. LedermannCancer Research UK and UCL Cancer Trials Centre - London, UK
Daniela MontagnaPoliclinico San Matteo - Pavia,Italy
Dietger Niederwieser University of Leipzig - Leipzig, Germany
Michael I. NishimuraThe University of Chicago - Chicago, USA
Paolo PedrazzoliOspedale Ca’ Granda di Niguarda - Milano, Italy
Francesca ReIstituto Scientifico Universitario San Raffaele - Milano, Italy
Nicholas Restifo National Institutes of Health - Bethesda, USA
Olle Ringdén Karolinska Institutet - Huddinge, Sweden
Maria Grazia RoncaroloIstituto Scientifico Universitario San Raffaele - Milano, Italy
Giovanni RostiOspedale Civile S. Maria delle Croci -Ravenna, Italy
Brenda M. Sandmaier Fred Hutchinson Cancer Research Center - Seattle, USA
Salvatore SienaOspedale Ca’ Granda di Niguarda - Milano, Italy
Shimon Slavin Hadassah University Hospital - Jerusalem, Israel
Yoshiyuki TakahashiNational Institutes of Health - Bethesda, USA
Naoto T. Ueno M.D. Anderson Cancer Centre - Houston, USA
Andrea VelardiUniversità degli Studi di Perugia - Perugia, Italy
Eric D. Wieder M.D. Anderson Cancer Centre - Houston, USA
Faculty
gen years after the first report on allogeneic transplantation in solid tumors, and after a considerable experience of thisstrategy in various tumor types, it is time to reconsider feasibility,toxicity, and clinical results of allografting in solid tumors. In this workshop, investigators who have initiated and refined this strategy will present most recent results, and discuss the following topics:
• has the introduction of reduced-intensity regimens really changed the toxicity and mortality of allografting?
• which tumors can be considered targets of allografting, and at which stage?
• is it possible to design randomised studies of this strategy in any tumor type?
• how favourably the results of allografting compare with recent results of cancer immunotherapy, and with the results of targeted therapy?
• is any tumor-associated antigen been identified as target of immune response?
The presentations and the discussion will take place in an informal atmosphere (no tie is required!), in a beautiful place like Lago Maggiore during fall season.Our aim is to build up a consensus on future clinical studies and related research in allogeneic transplant in solid tumors.
Marco BregniNaoto T. UenoRichard W. Childs
Introduction